BioInvent Stumbles In Busy Multiple Myeloma Space
The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.
The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.